Document is current
Any future updates will be listed below
-
Authors
Pape, Luca Julius https://orcid.org/0000-0002-3805-7833
Gebhardt, Anna Josephine https://orcid.org/0009-0001-5350-8911
Dannenberg, Marten
Risch, Henry
Duttmann, Anya
Weisel, Katja https://orcid.org/0000-0001-9422-6614
Hambach, Julia https://orcid.org/0009-0006-0305-5850
Koch-Nolte, Friedrich https://orcid.org/0000-0003-1730-6674
Bannas, Peter https://orcid.org/0000-0002-7102-534X
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 4 June 2025
Accepted: 17 October 2025
First Online: 18 November 2025
Declarations
:
: FK-N receives a share of antibody sales via MediGate GmbH, a wholly-owned subsidiary of University Medical Center Hamburg-Eppendorf. PB and FK-N are co-inventors on a patent application on CD38-specific nanobodies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
